



## P R E S S   R E L E A S E

March 17, 2004  
Oliver Heieck, Corp. Communications  
Tel.: +49 - 6172 - 6082101  
Fax: +49 - 6172 - 6082294  
e-mail: pr-fre@fresenius.de  
www.fresenius-ag.com

### **Fresenius AG appoints new Member of the Management Board**

Fresenius announces that its Supervisory Board unanimously appointed with immediate effect Dr. Ben Lipps a member of the Management Board of Fresenius AG in its March 16, 2004 meeting. Dr. Lipps will continue in his role as Chairman of the Management Board and CEO of Fresenius Medical Care AG.

“Ben Lipps has built our dialysis business in the United States from small beginnings to a key Fresenius revenue and earnings contributor”, commented Dr. Ulf M. Schneider, Chairman of the Management Board of Fresenius AG. “With his energy, his exceptional dedication and more than 35 years experience in dialysis Ben Lipps will continue to expand Fresenius Medical Care’s leadership position. I am very pleased that he will also bring his extensive experience and strategic initiatives to the Management Board of Fresenius AG.”

Dr. Lipps joined Fresenius USA in 1985 and held several senior executive positions with the company. He has been a member of the Management Board of Fresenius Medical Care since the company was founded in 1996 and was appointed Chairman in 1999.

The Management Board of Fresenius AG now includes the following members:

Dr. Ulf M. Schneider, Chairman

Rainer Baule, CEO Fresenius Kabi

Rainer Hohmann, CEO Fresenius ProServe

Dr. Ben Lipps, CEO Fresenius Medical Care

Udo Werlé, CFO and Labor Relations Director

###

Fresenius is an internationally operating health care group with products and services for dialysis, the hospital and the ambulatory medical care of patients. Sales amounted to 7.1 billion euros in 2003. On December 31, 2003 the Fresenius Group had 66,264 employees worldwide.

###

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius AG does not undertake any responsibility to update the forward-looking statements in this release.